Clinical and Molecular Hepatology

Article	Citations
Letter: cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis	307
Targeting TM4SF1 to overcome immunotherapy resistance in hepatocellular carcinoma	205
Reply to correspondence on “Circulating cell-free mitochondrial DNA for diagnosing hepatocellular carcinoma and assessing prognosis”	176
Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial	161
Metabolic dysfunction-associated steatotic liver disease across women’s reproductive lifespan and issues	160
Letter regarding “Prevalence of clinically significant liver fibrosis in the general population”	116
Urgent need for education on hepatocellular carcinoma surveillance among high-risk population in China	74
Identification of KCTD17 as a Ras stabilizer in hepatocellular carcinoma: Editorial on “KCTD17-mediated Ras stabilization promotes hepatocellular carcinoma progression”	66
Correspondence to letter to the editor on “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis”	64
Correspondence to letter to the editor on “Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis”	64
Correspondence to letter to the editor 2 on “Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma”	57
Reply to correspondence on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis”	56
Correspondence to editorial on “UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL”	53
A complement to epigenetics in metabolic dysfunction-associated steatotic liver disease: Editorial on “DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dy	50
Comment: Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus	45
Correspondence to editorial 2 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial”	44
Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial”	44
Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”	43
Correspondence to editorial on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis	42
Metabolic dysfunction-associated steatotic liver disease exhibits sex-specific microbial heterogeneity within intestinal compartments	41
Unveiling the Intratumor Microbiome in Liver Cancer: Current Insights and Prospective Applications	39
Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation	36
The rise of non-invasive tools in the diagnosis of portal hypertension: Validation of the Baveno VII consensus	35
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future	34
Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer	33

Correspondence on Letter regarding “Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis”	32
Surveillance for hepatocellular carcinoma: It is time to move forward	32
Optimizing off-treatment outcome predictions: The potential of time-varying HBcrAg and the need for more research	32
Both liver parenchymal and non-parenchymal cells express JCAD protein under various circumstances	32
Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations	31
Correspondence on Letter 1 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”	30
Starting the journey: Understanding the roles of complement proteins in liver diseases through mendelian randomization	29
Another oral antiviral treatment, but still far away from hepatitis B virus cure	29
Reappraisal of sepsis-3 and CLIF-SOFA as predictors of mortality in patients with cirrhosis and infection presenting to the emergency department: A multicenter study	29
From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?	28
Nonalcoholic fatty liver disease and early prediction of gestational diabetes mellitus using machine learning methods	28
Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma	27
Approaches to quantifying hepatitis B virus covalently closed circular DNA	26
Factors associated with unrecognized cirrhosis in patients with hepatocellular carcinoma	26
The effects of moderate alcohol consumption on non-alcoholic fatty liver disease	26
Correspondence on Letter regarding “Toward hepatitis C virus elimination using artificial intelligence”	26
Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations	25
The imitator of immune-tolerant chronic hepatitis B: A killer in disguise	25
Can hepatocellular carcinoma recurrence be prevented after liver transplantation?	24
Unlocking the future: Machine learning sheds light on prognostication for early-stage hepatocellular carcinoma: Editorial on “Conventional and machine learning-based risk scores for patients with earl	23
Unveiling etiology-specific blood biomarkers in hepatocellular carcinoma: A gateway to personalized medicine: Editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific sign	23
TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD	23
Nucleos(t)ide analog therapy of chronic hepatitis B and extrahepatic cancer risk: Is tenofovir better than entecavir?: Editorial on “Extrahepatic malignancies and antiviral drugs for chronic hepatitis	23
Modified quick-SOFA score: Can it enhance prognostic assessment for hospitalized patients with chronic liver diseases?: Editorial on “Dynamic analysis of acute deterioration in chronic liver disease p	22
Correspondence to editorial on “Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets”	22
Class II transactivator restricts viral replication, extending its effect to HBV: Editorial on “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”	22
Correspondence to editorial on “Liver sinusoidal endothelial cell: An important yet often overlooked player in the liver fibrosis”	22
Correspondence to editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma”	22
Meeting the challenges of hepatocellular carcinoma post sustained virologic response in the post-direct- acting antiviral era: A path forward: Editorial on “Unmet needs in the post-direct-acting antiv	22
Decreasing performance of HCC prediction models during antiviral therapy for hepatitis B: what else to keep in mind: Editorial on “Hepatocellular carcinoma prediction model performance decreases with	22
Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: A multinational population-based cohort study from South Korea, Japan, and the UK	21
Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systemati	21
Metformin and statins and their role in reducing hepatocellular carcinoma risk: Randomized trials are needed: Editorial on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepati	21
Diagnostic accuracy of vibration-controlled transient elastography for staging liver fibrosis in autoimmune liver diseases: A systematic review and meta-analysis	21
Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment	20
Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis	20
Imaging diagnosis of hepatocellular carcinoma: Future directions with special emphasis on hepatobiliary magnetic resonance imaging and contrast-enhanced ultrasound	19
What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea?	19
Neuropilins as potential biomarkers in hepatocellular carcinoma: a systematic review of basic and clinical implications	19
Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review	19
Screening strategy for non-alcoholic fatty liver disease	19
Chemoembolization combined with radiofrequency ablation is the best option for the local treatment of early hepatocellular carcinoma?	18
The role of the hepatic autonomic nervous system	18
Single-cell phenotypes of peripheral blood immune cells in early and late stages of non-alcoholic fatty liver disease	18
Bariatric surgery for non-alcoholic fatty liver disease: Indications and post-operative management	18
Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology	16
Systematic review with meta-analysis: Non-alcoholic fatty liver disease and the association with pregnancy outcomes	16
Nonalcoholic fatty liver disease-based risk prediction of adverse pregnancy outcomes: Ready for prime time?	16
Prognostic role of computed tomography analysis using deep learning algorithm in patients with chronic hepatitis B viral infection	16
A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective	16

Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity	15
Comparison of four histological scoring systems for autoimmune hepatitis to improve diagnostic sensitivity	15
Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hep	15
Association between new-onset liver cirrhosis and suicide risk in South Korea: A nationwide cohort study	15
Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers	15
Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus	15
Microbiome and metabolomics in alcoholic liver disease	14
Correspondence on Editorial regarding “Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients”	14
MARC1 downregulation reduces hepatocyte lipid content by increasing beta-oxidation	14
Significant down-regulation of growth hormone receptor expression revealed as a new unfavorable prognos- tic factor in hepatitis C virus-related hepatocellular carcinoma	14
Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals	14
Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”	14
The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults	14
U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases	14
Vibration-Controlled Transient Elastography in Shaping the Epidemiology and Management of Steatotic Liver Disease	14
Current status and outcome of liver transplantation in South Korea	14
Prediction of primary biliary cholangitis among health check-up population with anti-mitochondrial M2 antibody positive	13
Changes in the epidemiology and management of bacterial infections in cirrhosis	13
Prospect of emerging treatments for HBV functional cure	13
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma	13
The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection	13
Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study	13
Adding to the confusion in more than just the name	13
Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma	13
The role of transjugular intrahepatic portosystemic shunt in patients with portal hypertension: Advantages and pitfalls	13
KASL clinical practice guidelines for management of autoimmune hepatitis 2022	13
Clinical practice guidelines and real-life practice on hepatocellular carcinoma: the Hong Kong perspective	13
Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future	12
Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region	12
From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials	12
Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B	12
Anti-fibrotic treatments for chronic liver diseases: The present and the future	12
The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease	12
Preface	12
Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis	12
Liquid Biopsy in Hepatocellular Carcinoma: Challenges, Advances, and Clinical Implications	11
KASL clinical practice guidelines for management of chronic hepatitis B	11
Correspondence to editorial on “KCTD17-mediated Ras stabilization promotes hepatocellular carcinoma progression”	11
Discovery of dipeptidyl peptidase-4 inhibitor specific biomarker in non-alcoholic fatty liver disease mouse models using modified basket trial	11
Erratum to ‘Correspondence on Letter regarding “Evidence-based hyponatremia management in liver disease”’ [Clin Mol Hepatol 2023;29:1048-1049]	11
Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?	10
Toward hepatitis C virus elimination using artificial intelligence	10
Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)	10
Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases	10
JCAD, a new potential therapeutic target in cholestatic liver disease	10
Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact	10
The gene expression signature of metabolic dysfunction- associated steatotic liver disease from a multiomics perspective	10
Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer – author’s reply	10
Congratulatory remarks	9
Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study	9
Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma	9
Cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis	9
Reply: Letter: cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis	9
An analysis of polygenic risk scores for non-alcoholic fatty liver disease	8
HBeAg-positive grey-zone patients: Treatment beyond guideline recommendations?	7
Evidence-based hyponatremia management in liver disease	7
Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase”	7
Correspondence on Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”	7
MAFLD: How is it different from NAFLD?	7
The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B	7
Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease	7
COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis	7
Acute on chronic liver failure in cirrhosis	7
Correspondence on Editorial regarding “Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations”	7
Letter regarding “Evidence-based hyponatremia management in liver disease”	7
Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future	7
Letter 1 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”	7
Baveno VII criteria to predict decompensation in compensated advanced chronic liver disease: Still some shades of grey	7
Letter regarding “Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis”	7
Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma	6
Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizuma	6
Risk of hepatocellular carcinoma in untreated patients with chronic hepatitis B: Independent of HBeAg status?	6
The fibrosis-4 index for advanced liver fibrosis in NAFLD with T2DM: Half a loaf is better than no bread	6
Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial	6
Serum milk fat globule-EGF factor 8 protein as a potential biomarker for metabolic syndrome	6
Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis	6
Sex-specific associations of metabolic dysfunction-associated steatotic liver disease with cardiovascular outcomes	6
Modulation of PRL-1 within placental MSCs instigates the transition between EMT and MET subsequent to hepatic fibrosis	6
Correspondence to letter to the editor on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”	6
Steatotic liver disease in chronic hepatitis C related hepatocellular carcinoma: Inflictor or bystander?: Correspondence to editorial on “Dynamic change of metabolic dysfunction-associated steatotic l	6

Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiveness	6
Hepatocytes infected with hepatitis C virus change immunological features in the liver microenvironment	6
Current Burden of MASLD, MetALD, and Hepatic Fibrosis among US Adults with Prediabetes and Diabetes, 2017-2023	5
Leaky gut-derived tumor necrosis factor-α causes sarcopenia in patients with liver cirrhosis	5
Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis	5
Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences	5
The effect of moderate alcohol consumption on nonalcoholic fatty liver disease	5
Evaluation of the histological scoring systems of autoimmune hepatitis: A significant step towards the optimization of clinical diagnosis	5
Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease	5
Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy	5
Loco-regional therapies competing with radiofrequency ablation in potential indications for hepatocellular carcinoma: a network meta-analysis	5
Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy	5
The current trends in the health burden of primary liver cancer across the globe	5
Current evidence and the potential role of proton beam therapy for hepatocellular carcinoma	4
Congratulatory remarks	4
Incretin-based therapy in the management of metabolic dysfunction-associated steatotic liver disease (MASLD): one piece of the puzzle: Editorial on “Comparison of glucagon-like peptide-1 receptor agon	4
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective	4
KCTD17-mediated Ras stabilization promotes hepatocellular carcinoma progression	4
Risk factors in nonalcoholic fatty liver disease	4
Correspondence to editorial on “Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and magnetic resonance imaging”	4
Correspondence to editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study”	4
Metabolic dysfunction-associated fatty liver disease related hepatocellular carcinoma in China: An increasing problem: Letter to the edior on “Global prevalence of metabolic dysfunction-associated fat	4
Lean or Non-obese Nonalcoholic Fatty Liver Disease Patients: Are They Really Lean?	4
Changing from NAFLD to MASLD: Cumulative incidence of gallstones between patients with NAFLD and those with MASLD in Asia	4
Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment	4
Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease	4
The role of SPP1 in MASLD pathogenesis: Therapeutic insights into ursolic acid’s mechanisms of action: Correspondence to editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 c	4
Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease: Letter to the ed	4
Correspondence to editorial on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study”	4
ALCOHOL-ASSOCIATED LIVER DISEASE: NATURAL HISTORY, MANAGEMENT AND NOVEL TARGETED THERAPIES	4
Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma	3
The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review	3
Reconsidering Treatment Indications for Chronic Hepatitis B: Insights from the TORCH-B Roll-Over Study	3
Current Burden of Steatotic Liver Disease and Fibrosis among Adults in the United States, 2017-2023	3
Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases	3
Liver organoids: Current advances and future applications for hepatology	3
Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients	3
RNA interference as a novel treatment strategy for chronic hepatitis B infection	3
Mechanisms of HCC and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis B	3
A decade of liver organoids: Advances in disease modeling	3
Toward user-friendly and evidence-based practice guidelines for hepatocellular carcinoma	3
HCV Self-Testing: Bridging Screening Gaps and Ensuring Cost-Effectiveness for Both High-Risk and Universal Populations	3
Erratum to ‘History and future of hepatitis B virus control in South Korea’ [Clin Mol Hepatol 2021;27:620-622]	3
A leap in the dark: Bariatric surgery for treatment of metabolic dysfunction-associated steatotic liver disease related cirrhosis	3
Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets	3
Waiting for the changes after the adoption of steatotic liver disease	3
The growing burden of non-alcoholic fatty liver disease on mortality	3
Letter regarding “Risk factors in nonalcoholic fatty liver disease”	3
The emerging roles of extracellular vesicles as intercellular messengers in liver physiology and pathology	3
Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study	3
Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment	3
Epidemiology of Metabolic Dysfunction Associated Steatotic Liver Disease	3
Reply to correspondence on “Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients”	3
Liver sinusoidal endothelial cell: An important yet often overlooked player in the liver fibrosis	2
Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity	2
Examining the therapeutic landscape of beta-blockers in portal hypertension	2
Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease	2
Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease	2
Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance	2
Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and magnetic resonance imaging	2
Preface	2
Letter regarding “Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma”	2
Vibration-controlled transient elastography for significant fibrosis in treatment-naïve chronic hepatitis B patients: A systematic review and meta-analysis	2
GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers	2
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis	2
Direct comparison of biopsy techniques for hepatic malignancies	2
Deep learning-based prediction of molecular cancer biomarkers from tissue slides: A new tool for precision oncology	2
Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program	2
Current status and perspective on molecular targets and therapeutic intervention strategy in hepatic ischemia-reperfusion injury	2
Epidemiology and updated management for autoimmune liver disease	2
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective	2
Update on liver disease management during the pandemic of coronavirus disease 2019 (COVID-19): 2021 KASL guideline	2
Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase	2
Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus: A systematic review and meta-analysis	2
Surgical resection versus ablation for early hepatocellular carcinoma: The debate is still open	2
Comparison between obese and non-obese nonalcoholic fatty liver disease	2
Plasma lipidomics and fungal peptide-based community analysis identifies distinct signatures of early mortality in acute liver failure	2
Exploring the prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma	2
Preface	2
Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs	2
Dipeptidyl peptidase-4 inhibitors are associated with improved survival of patients with diabetes mellitus and hepatocellular carcinoma receiving immunotherapy: Letter to the editor on “Statin and asp	2
Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients	2
Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis	2
Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma	2
Correspondence on Editorial regarding “Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease”	2
Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”	2
Special thanks	2
Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease	2
Cost-effectiveness of chronic hepatitis C screening and treatment	2
Global Inequality in the Burden of Hepatitis B From 1990 to 2021: Findings From the Global Burden of Disease Study 2021	2
Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma	2
Prevalence trends of non-alcoholic fatty liver disease among young men in Korea: A Korean military population-based cross-sectional study	1
Nonalcoholic fatty liver disease and non-liver comorbidities	1
Decreased vitamin D-binding protein level portends poor outcome in acute-on-chronic liver failure caused by hepatitis B virus	1
What is new in the 2024 Chinese guidelines for fatty liver disease?	1